UPB — Upstream Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2022626 ·
Last close
$2.10
Market Cap
$115.10M
52W High
$33.68
52W Low
$2.01
ADV30
1,359,163
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 395,000 | — | -43,379,000 | -41,192,000 | 245,992,000 | 47,416,000 | 12,017,000 |
| Jun 2026 | 773,000 | — | -42,368,000 | -39,702,000 | 281,171,000 | 79,397,000 | 10,214,000 |
| Mar 2026 | 1,034,000 | — | -43,615,000 | -40,591,000 | 318,054,000 | 96,724,000 | 14,059,000 |
| Dec 2025 | 668,000 | — | -46,167,000 | -42,459,000 | 353,772,000 | 101,578,000 | 14,001,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-168,334,000
Investing CF
$139,283,000
Financing CF
$4,303,000
CapEx
$-118,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.01
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-455,708,000
Inventory
—
Receivables
$1,468,000
ST Investments
$159,949,000
EBIT TTM
$-175,529,000
Pretax Income TTM
$-163,944,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,870,000
EBITDA
$-175,324,000
Free Cash Flow
$-114,344,624
Enterprise Value
$-54,200,332
Total Cash
$207,364,992
Total Debt
$789,000
Shares Out
54,811,391
Trailing EPS
$-3.01
Book Value
$4.27
ROE
-53.5%
ROA
-34.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,854,000 | -160,361,000 | -143,443,000 | 353,772,000 | 14,001,000 | 339,771,000 | -133,275,000 |
| Dec 2024 | 2,370,000 | -77,764,000 | -62,806,000 | 481,719,000 | 11,867,000 | 469,852,000 | -59,172,000 |
| Dec 2023 | 2,380,000 | -40,114,000 | -20,537,000 | 117,198,000 | 240,324,000 | -123,126,000 | -37,926,000 |
| Dec 2022 | 1,212,000 | -23,909,000 | -23,868,000 | 18,478,000 | 124,633,000 | -106,155,000 | -19,021,000 |
TTM Snapshot
Revenues TTM
$3,158,000
NetIncome TTM
$-156,500,000
OpCashFlow TTM
—
Assets (Latest)
$281,171,000
Forward EPS
$-2.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPRB | SPRUCE BIOSCIENCES, INC. | $116.37M | $40.49 | — |
| SCNX | Scienture Holdings, Inc. | $113.34M | $2.76 | — |
| AKBA | Akebia Therapeutics, Inc. | $111.18M | $0.40 | — |
| FHTX | Foghorn Therapeutics Inc. | $109.73M | $1.83 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $106.07M | $2.45 | — |
News headlines (Yahoo Finance, 1h cache)
Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates
2026-11-10 12:25 · Yahoo
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
2026-11-10 12:00 · Yahoo
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
2026-09-08 07:30 · Yahoo
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
2026-09-01 11:31 · Yahoo
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
2026-08-11 11:00 · Yahoo
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-14 16:00 · Yahoo
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?
2026-06-23 15:36 · Yahoo
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 11:00 · Yahoo
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
2026-04-17 11:00 · Yahoo
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
2026-05-13 12:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.